Digestive Diseases and Sciences

, Volume 57, Issue 8, pp 1996–2010

Advances in the Current Treatment of Autoimmune Hepatitis

Review

Abstract

Current treatment strategies for autoimmune hepatitis are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. The objective of this review is to describe advances that have improved treatment outcomes by defining the optimum objectives of initial therapy, managing relapse more effectively, identifying problematic patients early, and incorporating the new pharmacological interventions that have emerged as frontline and salvage therapies. Initial corticosteroid treatment should be continued until serum aminotransferase, γ-globulin, and immunoglobulin G levels are normal, and maintenance of this improvement for 3–8 months before liver tissue assessment. Improvement to normal liver tissue is the ideal histological result that justifies drug withdrawal, but it is achievable in only 22 % of patients. Minimum portal hepatitis, inactive cirrhosis, or minimally active cirrhosis is the most common treatment end point. Relapse after drug withdrawal warrants institution of a long-term maintenance regimen, preferably with azathioprine. Mathematical models can identify problematic adult patients early, as also can clinical phenotype (age ≤30 years and HLA DRB1*03), rapidity of treatment response (≤24 months), presence of antibodies to soluble liver antigen, and non-white ethnicity. The calcineurin inhibitors (cyclosporine and tacrolimus) can be effective in steroid-refractory disease; mycophenolate mofetil can be corticosteroid-sparing and effective for azathioprine intolerance; budesonide combined with azathioprine can be effective for treatment-naïve, non-cirrhotic patients. Standard treatment regimens for autoimmune hepatitis can be upgraded without adjustments that require major new expertise.

Keywords

Advances Autoimmune hepatitis Treatment Nonstandard medications 

References

  1. 1.
    Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185.PubMedGoogle Scholar
  2. 2.
    Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.PubMedGoogle Scholar
  3. 3.
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737.PubMedCrossRefGoogle Scholar
  4. 4.
    Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646–652.PubMedCrossRefGoogle Scholar
  5. 5.
    Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50:547–551.PubMedCrossRefGoogle Scholar
  6. 6.
    Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848–857.PubMedCrossRefGoogle Scholar
  7. 7.
    Floreani A, Niro G. Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051–1057.PubMedCrossRefGoogle Scholar
  8. 8.
    Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410–1414.PubMedCrossRefGoogle Scholar
  9. 9.
    Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American association for the study of liver diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.PubMedCrossRefGoogle Scholar
  10. 10.
    Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207–215.PubMedCrossRefGoogle Scholar
  11. 11.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138–1145.PubMedCrossRefGoogle Scholar
  12. 12.
    Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622–627.PubMedCrossRefGoogle Scholar
  13. 13.
    Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319–333.PubMedCrossRefGoogle Scholar
  14. 14.
    Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 1980;78:518–523.PubMedGoogle Scholar
  15. 15.
    Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685–689.PubMedCrossRefGoogle Scholar
  16. 16.
    Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890–897.PubMedCrossRefGoogle Scholar
  17. 17.
    Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269–291.PubMedCrossRefGoogle Scholar
  18. 18.
    Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712–2726.PubMedCrossRefGoogle Scholar
  19. 19.
    Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design. 2011;17:3120–3140.CrossRefGoogle Scholar
  20. 20.
    Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.PubMedCrossRefGoogle Scholar
  21. 21.
    Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93:890–893.PubMedGoogle Scholar
  23. 23.
    Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317–320.PubMedCrossRefGoogle Scholar
  24. 24.
    Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–776.PubMedGoogle Scholar
  25. 25.
    Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459–461.PubMedCrossRefGoogle Scholar
  26. 26.
    Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr. 1999;135:111–114.PubMedCrossRefGoogle Scholar
  27. 27.
    Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241–248.PubMedCrossRefGoogle Scholar
  28. 28.
    Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321–1327.PubMedCrossRefGoogle Scholar
  29. 29.
    Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001;7:556–558.PubMedCrossRefGoogle Scholar
  30. 30.
    Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805–809.PubMedCrossRefGoogle Scholar
  31. 31.
    Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232–3236.PubMedGoogle Scholar
  32. 32.
    Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405–407.PubMedCrossRefGoogle Scholar
  33. 33.
    Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585–590.PubMedCrossRefGoogle Scholar
  34. 34.
    Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927–934.PubMedCrossRefGoogle Scholar
  35. 35.
    Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12:1362–1366.PubMedGoogle Scholar
  36. 36.
    Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008;22:388–392.PubMedGoogle Scholar
  37. 37.
    Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.PubMedCrossRefGoogle Scholar
  38. 38.
    Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann Pharmacother. 2011;45:1144–1150.PubMedCrossRefGoogle Scholar
  39. 39.
    Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371–375.PubMedCrossRefGoogle Scholar
  40. 40.
    Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321–326.PubMedGoogle Scholar
  41. 41.
    Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825.PubMedCrossRefGoogle Scholar
  42. 42.
    Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799–802.PubMedCrossRefGoogle Scholar
  43. 43.
    Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063–3070.PubMedCrossRefGoogle Scholar
  44. 44.
    Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036–1040.PubMedCrossRefGoogle Scholar
  45. 45.
    Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156–160.PubMedCrossRefGoogle Scholar
  46. 46.
    Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519–2522.PubMedCrossRefGoogle Scholar
  47. 47.
    Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588–592.PubMedGoogle Scholar
  48. 48.
    Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011;55:636–646.PubMedCrossRefGoogle Scholar
  49. 49.
    Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335–343.PubMedCrossRefGoogle Scholar
  50. 50.
    Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol. 2011;5:517–522.PubMedCrossRefGoogle Scholar
  51. 51.
    Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92:215–219.PubMedGoogle Scholar
  52. 52.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005–1012.PubMedCrossRefGoogle Scholar
  53. 53.
    Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339–341, 344–338.Google Scholar
  54. 54.
    Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001;34:354–355.PubMedCrossRefGoogle Scholar
  55. 55.
    Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80:687–692.PubMedGoogle Scholar
  56. 56.
    Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42:926–930.PubMedCrossRefGoogle Scholar
  57. 57.
    Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981;304:5–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761–1769.PubMedCrossRefGoogle Scholar
  59. 59.
    Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99:1510–1516.PubMedCrossRefGoogle Scholar
  60. 60.
    Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222–1227.PubMedGoogle Scholar
  61. 61.
    Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22:973–980.PubMedCrossRefGoogle Scholar
  62. 62.
    Baggenstoss AH, Soloway RD, Summerskill WH, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972;3:183–198.PubMedCrossRefGoogle Scholar
  63. 63.
    Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23:116–123.PubMedCrossRefGoogle Scholar
  64. 64.
    Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis. 1971;16:1082–1086.PubMedCrossRefGoogle Scholar
  65. 65.
    Theodossi A, Skene AM, Portmann B, et al. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology. 1980;79:232–241.PubMedGoogle Scholar
  66. 66.
    Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.PubMedCrossRefGoogle Scholar
  67. 67.
    Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010;52:1857; author reply 1857–1858.Google Scholar
  68. 68.
    Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol. 2005;43:951–957.PubMedCrossRefGoogle Scholar
  69. 69.
    Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727–737.PubMedCrossRefGoogle Scholar
  70. 70.
    Czaja AJ. Autoimmune hepatitis. Part A: Pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.PubMedCrossRefGoogle Scholar
  71. 71.
    Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007;27:507–515.PubMedCrossRefGoogle Scholar
  72. 72.
    Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8:781–784.PubMedCrossRefGoogle Scholar
  73. 73.
    Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963.PubMedCrossRefGoogle Scholar
  74. 74.
    Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990;11:1044–1049.PubMedCrossRefGoogle Scholar
  75. 75.
    Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005;25:734–739.PubMedCrossRefGoogle Scholar
  76. 76.
    Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221–227.PubMedGoogle Scholar
  77. 77.
    Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717.PubMedGoogle Scholar
  78. 78.
    Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926–934.PubMedCrossRefGoogle Scholar
  79. 79.
    Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215–221.PubMedCrossRefGoogle Scholar
  80. 80.
    Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448–453.PubMedGoogle Scholar
  81. 81.
    Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–2161.PubMedCrossRefGoogle Scholar
  82. 82.
    Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161–167.PubMedCrossRefGoogle Scholar
  83. 83.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502–1507.PubMedCrossRefGoogle Scholar
  84. 84.
    Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317–323.PubMedCrossRefGoogle Scholar
  85. 85.
    Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–538.PubMedCrossRefGoogle Scholar
  86. 86.
    De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290–296.PubMedCrossRefGoogle Scholar
  87. 87.
    Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71–96.PubMedGoogle Scholar
  88. 88.
    Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8:245–249.PubMedCrossRefGoogle Scholar
  89. 89.
    Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989–2993.PubMedCrossRefGoogle Scholar
  90. 90.
    Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24–26.PubMedCrossRefGoogle Scholar
  91. 91.
    Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.PubMedCrossRefGoogle Scholar
  92. 92.
    Manns M, Gerken G, Kyriatsoulis A, Staritz M. Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292–294.PubMedCrossRefGoogle Scholar
  93. 93.
    Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18:1–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–1515.PubMedCrossRefGoogle Scholar
  95. 95.
    Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59–65.PubMedCrossRefGoogle Scholar
  96. 96.
    Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001;33:591–596.PubMedCrossRefGoogle Scholar
  97. 97.
    Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364–374.PubMedCrossRefGoogle Scholar
  98. 98.
    Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA. 1992;89:9739–9743.PubMedCrossRefGoogle Scholar
  99. 99.
    Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264.PubMedCrossRefGoogle Scholar
  100. 100.
    Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475–483.PubMedCrossRefGoogle Scholar
  101. 101.
    Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664.PubMedCrossRefGoogle Scholar
  102. 102.
    Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413–419.PubMedCrossRefGoogle Scholar
  103. 103.
    Liaskos C, Bogdanos DP, Rigopoulou EI, et al. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis (abstract). J Hepatol. 2007;46:S250.CrossRefGoogle Scholar
  104. 104.
    Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int. 2009;29:857–864.PubMedCrossRefGoogle Scholar
  105. 105.
    Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85–92.PubMedCrossRefGoogle Scholar
  106. 106.
    Mix H, Weiler-Normann C, Thimme R, et al. Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology. 2008;135:2107–2118.PubMedCrossRefGoogle Scholar
  107. 107.
    Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313–333.PubMedGoogle Scholar
  108. 108.
    Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315–330.PubMedCrossRefGoogle Scholar
  109. 109.
    Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314–2328.PubMedCrossRefGoogle Scholar
  110. 110.
    Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689–700.PubMedCrossRefGoogle Scholar
  111. 111.
    Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96:3390–3394.PubMedCrossRefGoogle Scholar
  112. 112.
    Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828–1835.PubMedCrossRefGoogle Scholar
  113. 113.
    Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–2407.PubMedCrossRefGoogle Scholar
  114. 114.
    Minuk GY, Liu S, Kaita K, et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol. 2008;22:829–834.PubMedGoogle Scholar
  115. 115.
    Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002;50:713–717.PubMedCrossRefGoogle Scholar
  116. 116.
    Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490–495.PubMedCrossRefGoogle Scholar
  117. 117.
    Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun. 2003;21:77–82.PubMedCrossRefGoogle Scholar
  118. 118.
    Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906–1913.PubMedCrossRefGoogle Scholar
  119. 119.
    Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302–308.PubMedCrossRefGoogle Scholar
  120. 120.
    Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146–150.PubMedCrossRefGoogle Scholar
  121. 121.
    Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374–1380.PubMedCrossRefGoogle Scholar
  122. 122.
    D’Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int. 2005;25:325–330.PubMedCrossRefGoogle Scholar
  123. 123.
    Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology. 2007;45:1282–1289.PubMedCrossRefGoogle Scholar
  124. 124.
    Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058–1066.PubMedCrossRefGoogle Scholar
  125. 125.
    Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999–2004. Am J Gastroenterol. 2008;103:2231–2238.PubMedCrossRefGoogle Scholar
  126. 126.
    Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–1187.PubMedCrossRefGoogle Scholar
  127. 127.
    Huppertz HI, Treichel U, Gassel AM, Jeschke R. Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204–208.PubMedCrossRefGoogle Scholar
  128. 128.
    Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512–1517.Google Scholar
  129. 129.
    Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005;11:1862–1866.PubMedGoogle Scholar
  130. 130.
    Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007;52:179–184.PubMedCrossRefGoogle Scholar
  131. 131.
    Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology. 2011;140:1874–1876.PubMedCrossRefGoogle Scholar
  132. 132.
    Manns MP, Strassburg CP. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011;29:411–415.PubMedCrossRefGoogle Scholar
  133. 133.
    Turner JD, Thomas AP, Reeves JP, Hantash BM. Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells. Cell Calcium. 2009;46:242–247.PubMedCrossRefGoogle Scholar
  134. 134.
    Martinez–Martinez S, Redondo JM. Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem. 2004;11:997–1007.PubMedCrossRefGoogle Scholar
  135. 135.
    Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol. 2004;36:1166–1170.PubMedCrossRefGoogle Scholar
  136. 136.
    Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472–484.PubMedCrossRefGoogle Scholar
  137. 137.
    de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31:416–435.PubMedCrossRefGoogle Scholar
  138. 138.
    Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm. 1983;2:515–524.PubMedGoogle Scholar
  139. 139.
    Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63–83.PubMedCrossRefGoogle Scholar
  140. 140.
    Almawi WY, Assi JW, Chudzik DM, Jaoude MM, Rieder MJ. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1. Cell Transplant. 2001;10:615–623.PubMedGoogle Scholar
  141. 141.
    Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328–335.PubMedCrossRefGoogle Scholar
  142. 142.
    Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807–815.PubMedCrossRefGoogle Scholar
  143. 143.
    Galat A, Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010;67:3467–3488.PubMedCrossRefGoogle Scholar
  144. 144.
    Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755–757.PubMedCrossRefGoogle Scholar
  145. 145.
    Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994;265:674–676.PubMedCrossRefGoogle Scholar
  146. 146.
    Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol. 2003;57:93–98.PubMedCrossRefGoogle Scholar
  147. 147.
    Pissaia A, Jr, Aoudjehane L, Ben Othman S, et al. Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor beta on human intrahepatic fibroblasts cultured in vitro. Transplant Proc. 2010;42:4343–4346.Google Scholar
  148. 148.
    Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust. 1985;143:463–465.PubMedGoogle Scholar
  149. 149.
    Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040–1047.PubMedCrossRefGoogle Scholar
  150. 150.
    Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30:222–227.PubMedCrossRefGoogle Scholar
  151. 151.
    Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2006;43:635–639.PubMedCrossRefGoogle Scholar
  152. 152.
    Cuarterolo ML, Ciocca ME, Lopez SI, de Davila MT, Alvarez F. Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2011;9:145–149.PubMedCrossRefGoogle Scholar
  153. 153.
    Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723–727.PubMedCrossRefGoogle Scholar
  154. 154.
    Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995;12:348–357.PubMedCrossRefGoogle Scholar
  155. 155.
    Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.PubMedCrossRefGoogle Scholar
  156. 156.
    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.PubMedCrossRefGoogle Scholar
  157. 157.
    Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:s2–s8.PubMedCrossRefGoogle Scholar
  158. 158.
    Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transpl. 2006;20:25–29.CrossRefGoogle Scholar
  159. 159.
    Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8–10.PubMedCrossRefGoogle Scholar
  160. 160.
    Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010;85:627–629.PubMedCrossRefGoogle Scholar
  161. 161.
    Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A:1–7.PubMedCrossRefGoogle Scholar
  162. 162.
    Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–1248.PubMedCrossRefGoogle Scholar
  163. 163.
    Klieger-Grossmann C, Chitayat D, Lavign S, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32:794–797.PubMedGoogle Scholar
  164. 164.
    Lin AE, Singh KE, Strauss A, et al. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet A. 2011;155A:748–756.PubMedGoogle Scholar
  165. 165.
    Seikaly MG. Mycophenolate mofetil—is it worth the cost? The in-favor opinion. Pediatr Transplant. 1999;3:79–82.PubMedCrossRefGoogle Scholar
  166. 166.
    Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2006;7:145–156.PubMedCrossRefGoogle Scholar
  167. 167.
    Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485–518.PubMedCrossRefGoogle Scholar
  168. 168.
    Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312–1316.PubMedCrossRefGoogle Scholar
  169. 169.
    Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9:2681–2685.PubMedGoogle Scholar
  170. 170.
    Efe C, Ozaslan E, Kav T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. Epub. 10/06/2011.Google Scholar
  171. 171.
    Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol. 2011;54:837–839.PubMedCrossRefGoogle Scholar
  172. 172.
    Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816–823.PubMedCrossRefGoogle Scholar
  173. 173.
    Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.PubMedCrossRefGoogle Scholar
  174. 174.
    Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16:934–947.PubMedCrossRefGoogle Scholar
  175. 175.
    de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol. 2005;17:457–461.Google Scholar
  176. 176.
    Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81:445–454.PubMedCrossRefGoogle Scholar
  177. 177.
    Ronis MJ, Butura A, Sampey BP, et al. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med. 2005;39:619–630.PubMedCrossRefGoogle Scholar
  178. 178.
    Bemeur C, Vaquero J, Desjardins P, Butterworth RF. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. Metab Brain Dis. 2010;25:241–249.PubMedCrossRefGoogle Scholar
  179. 179.
    Baumgardner JN, Shankar K, Hennings L, et al. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138:1872–1879.PubMedGoogle Scholar
  180. 180.
    Setshedi M, Longato L, Petersen DR, et al. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res. Epub. 07/28/2011.Google Scholar
  181. 181.
    Desai D, Kaushal N, Gandhi UH, et al. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact. 2010;188:446–456.PubMedCrossRefGoogle Scholar
  182. 182.
    Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature. 1989;337:181–184.PubMedCrossRefGoogle Scholar
  183. 183.
    von Herrath MG, Coon B, Wolfe T, Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol. 2002;168:933–941.Google Scholar
  184. 184.
    Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004;4:403–407.PubMedCrossRefGoogle Scholar
  185. 185.
    Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA. 1994;91:123–127.PubMedCrossRefGoogle Scholar
  186. 186.
    Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–1698.PubMedCrossRefGoogle Scholar
  187. 187.
    Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–1769.PubMedCrossRefGoogle Scholar
  188. 188.
    Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001;410:604–608.PubMedCrossRefGoogle Scholar
  189. 189.
    Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143–155.PubMedCrossRefGoogle Scholar
  190. 190.
    Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:201–210.PubMedCrossRefGoogle Scholar
  191. 191.
    Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009:CD007277.Google Scholar
  192. 192.
    Chen W, Perruche S, Li J. CD4+ CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245–2249.PubMedCrossRefGoogle Scholar
  193. 193.
    Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37.PubMedCrossRefGoogle Scholar
  194. 194.
    Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–4491.PubMedGoogle Scholar
  195. 195.
    Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581–591.PubMedCrossRefGoogle Scholar
  196. 196.
    Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223–243.PubMedCrossRefGoogle Scholar
  197. 197.
    Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations